FDA Grants QTORIN Priority Review, Sets February 28, 2027, as Target Action Date

Key Facts

Palvella Therapeutics said on October 28 that the U.S. Food and Drug Administration accepted the new drug application for QTORIN rapamycin and granted it priority review, setting February 28, 2027, as the target date for action. The application covers an anhydrous gel containing 3.9% rapamycin for the treatment of microcystic lymphatic malformations. Acceptance moves the application into regulatory review, while marketing approval remains a decision that has not yet been made. According to the FDA, priority review targets action within 6 months, compared with 10 months for standard review. The agency says the designation does not change the standard of scientific and medical evidence required for approval, but directs resources to drug applications that, if approved, could provide a significant improvement over available treatments for a serious condition.

The company based its announcement on results from the Phase 3 SELVA study, saying all six prespecified efficacy endpoints achieved statistical significance, with a p-value of less than 0.001 for each. This indicates that the statistical results covered all the efficacy endpoints established in advance by the study, according to Palvella's statement. On the primary endpoint, 95% of participants aged 6 years and older who completed the efficacy assessment period showed improvement on the mLM-IGA scale. This percentage specifies the group covered by the measurement: older participants who completed the assessment period, not everyone who began the study. The company had said in its annual report that the study achieved an improvement of 2.13 points on the primary endpoint at Week 24, with a p-value of less than 0.001. That figure places the Week 24 assessment result in a specific time frame, while the application announcement presents the results for the six efficacy endpoints and the share of participants who showed improvement.

On safety, Palvella said the study recorded no serious drug-related adverse events. It added that blood rapamycin concentrations remained below 2 ng/mL at all measurement points in all participants. The company links the reported efficacy-scale results with the systemic exposure data recorded during the study. These results remain part of the application dossier under FDA review and do not, by themselves, constitute a regulatory decision on use or marketing. Priority review also shortens the review timeline target compared with the standard process, but does not lower the level of evidence required for approval, according to the agency.

Palvella describes microcystic lymphatic malformations as a serious, rare, lifelong condition and estimates that they affect more than 30,000 diagnosed children and adults in the United States. The company said the condition may be associated with persistent leakage, bleeding, recurrent infections and dysfunction. According to Palvella, QTORIN rapamycin could become the first FDA-approved treatment for the condition if it clears review and receives approval. This background gives the application potential therapeutic significance, but that remains tied to the outcome of the regulatory action the agency has targeted for February 2027. The drug has also received breakthrough therapy, fast track and orphan drug designations for microcystic lymphatic malformations, according to the company.

The FDA set February 28, 2027, as the target date for action on the application under the Prescription Drug User Fee Act. This is the anticipated regulatory date in the review process, not an advance announcement of its outcome. Palvella said it is preparing for a potential independent U.S. commercial launch in the first half of 2027, subject to FDA approval. This timeline links the target action date to the company's commercial plan, with the launch remaining contingent on approval. Palvella's pipeline includes other QTORIN rapamycin programs targeting clinically significant cutaneous venous malformations and angiokeratomas, as well as a QTORIN pitavastatin program for disseminated superficial actinic porokeratosis. The application for microcystic lymphatic malformations is part of the company's portfolio of programs, while the next milestone for this application is the action the FDA is targeting by February 28, 2027.